
Urovant Sciences Ltd. Net Income | UROV
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Urovant Sciences Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -147 M | -111 M | -37.1 M | -27 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27 M | -147 M | -80.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Pulmatrix
PULM
|
-1.17 M | $ 1.48 | 0.64 % | $ 5.41 B | ||
|
PolyPid Ltd.
PYPD
|
-34.2 M | $ 5.2 | 0.19 % | $ 85 M | ||
|
Repare Therapeutics
RPTX
|
-84.7 M | - | - | $ 112 M | ||
|
uniQure N.V.
QURE
|
-199 M | $ 22.8 | 0.39 % | $ 1.31 B | ||
|
Rocket Pharmaceuticals
RCKT
|
-223 M | $ 2.61 | 1.95 % | $ 290 M | ||
|
Arcus Biosciences
RCUS
|
-353 M | $ 24.74 | 1.23 % | $ 2.66 B | ||
|
Regeneron Pharmaceuticals
REGN
|
4.5 B | $ 726.47 | 0.05 % | $ 76 B | ||
|
Replimune Group
REPL
|
-314 M | $ 13.15 | 0.61 % | $ 1.22 B | ||
|
Rafael Holdings
RFL
|
-290 K | $ 1.47 | 0.65 % | $ 43.3 M | ||
|
REGENXBIO
RGNX
|
-194 M | $ 7.76 | 4.44 % | $ 400 M | ||
|
Rigel Pharmaceuticals
RIGL
|
367 M | $ 47.79 | 1.36 % | $ 860 M | ||
|
Relay Therapeutics
RLAY
|
-276 M | $ 19.39 | 2.27 % | $ 3.33 B | ||
|
Avidity Biosciences
RNA
|
-685 M | $ 7.97 | 1.66 % | $ 1.1 B | ||
|
Royalty Pharma plc
RPRX
|
771 M | $ 56.66 | 0.36 % | $ 24.4 B | ||
|
Revolution Medicines
RVMD
|
-1.13 B | $ 207.68 | 0.5 % | $ 39.5 B | ||
|
Rhythm Pharmaceuticals
RYTM
|
-197 K | $ 92.45 | 0.24 % | $ 6.01 B | ||
|
Rezolute
RZLT
|
-77.6 M | $ 4.33 | 7.98 % | $ 450 M | ||
|
Sana Biotechnology
SANA
|
-244 M | $ 2.88 | 1.21 % | $ 729 M | ||
|
Seer
SEER
|
-73.6 M | $ 2.33 | 3.56 % | $ 129 M | ||
|
SIGA Technologies
SIGA
|
23.3 M | $ 3.48 | 2.96 % | $ 249 M | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
-6.13 M | $ 78.95 | 9.65 % | $ 220 M | ||
|
Silence Therapeutics plc
SLN
|
-43.3 M | $ 10.14 | 0.78 % | $ 1.44 B | ||
|
SELLAS Life Sciences Group
SLS
|
-26.9 M | $ 11.63 | 3.62 % | $ 1.27 B | ||
|
Summit Therapeutics
SMMT
|
-1.08 B | $ 17.27 | 3.07 % | $ 12.9 B | ||
|
Syndax Pharmaceuticals
SNDX
|
-285 M | $ 17.83 | 1.31 % | $ 1.54 B | ||
|
Soligenix
SNGX
|
-11.1 M | $ 0.36 | 0.6 % | $ 1.87 M | ||
|
Sanofi
SNY
|
7.85 B | $ 39.51 | 1.19 % | $ 48.2 B | ||
|
Spruce Biosciences
SPRB
|
-39 M | $ 45.42 | 2.1 % | $ 34.8 M | ||
|
Spero Therapeutics
SPRO
|
8.57 M | $ 1.16 | 4.13 % | $ 65 M | ||
|
Sarepta Therapeutics
SRPT
|
-713 M | $ 17.49 | 0.7 % | $ 1.75 B | ||
|
Scholar Rock Holding Corporation
SRRK
|
-378 M | $ 43.4 | 1.41 % | $ 4.98 B | ||
|
Stoke Therapeutics
STOK
|
-6.88 M | $ 25.32 | 0.8 % | $ 1.5 B | ||
|
Sutro Biopharma
STRO
|
-191 M | $ 15.13 | 0.23 % | $ 129 M | ||
|
Shattuck Labs
STTK
|
-48.8 M | $ 6.5 | 1.04 % | $ 452 M | ||
|
Supernus Pharmaceuticals
SUPN
|
-38.6 M | $ 42.76 | 0.9 % | $ 2.41 B | ||
|
Sesen Bio
SESN
|
-60.5 M | - | 7.29 % | $ 127 M | ||
|
Savara
SVRA
|
-119 M | $ 4.78 | 0.1 % | $ 1.06 B | ||
|
China SXT Pharmaceuticals
SXTC
|
-6.21 M | $ 2.08 | 1.99 % | $ 1.41 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
108 B | $ 17.81 | 0.08 % | $ 28.1 B | ||
|
Protara Therapeutics
TARA
|
-57.4 M | $ 2.63 | 0.36 % | $ 113 M | ||
|
Tarsus Pharmaceuticals
TARS
|
-66 M | $ 74.46 | 1.99 % | $ 3.11 B | ||
|
Bio-Techne Corporation
TECH
|
182 M | $ 72.58 | 0.25 % | $ 11.3 B | ||
|
Tenax Therapeutics
TENX
|
-52.6 M | $ 1.96 | 2.59 % | $ 76.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
1.41 B | $ 39.66 | 0.33 % | $ 45.4 B | ||
|
TG Therapeutics
TGTX
|
447 M | $ 53.91 | 0.12 % | $ 7.78 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-124 M | $ 8.07 | 0.54 % | $ 68.7 M | ||
|
Trevi Therapeutics
TRVI
|
-42.8 M | $ 13.72 | 0.99 % | $ 1.85 B | ||
|
Taysha Gene Therapies
TSHA
|
-109 M | $ 4.49 | 0.11 % | $ 1.44 B | ||
|
UroGen Pharma Ltd.
URGN
|
-153 M | $ 42.78 | 3.33 % | $ 2.06 B | ||
|
United Therapeutics Corporation
UTHR
|
1.33 B | $ 536.4 | 0.37 % | $ 23.8 B |